Good find nbb. Thanks for sharing the link. I did a brief bit of research for comparison.

Ambrx Pharmaceutical Dec 10 2022

Some Background on Ambrx

Founded in 2003. It has been a very long journey to potential future success.

I’ve chosen some share prices to illustrate the long decline of Ambrx share price after it’s IPO in 2021 before it’s dramatic recent jump in SP.

Background

Our internal pipeline is focused on creating next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC.

We have established collaborations with multiple pharmaceutical companies including NovoCodex Biopharmaceuticals, Sino Biopharmaceuticals, and BeiGene in additional indications and development projects.

Description

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Ambrx Announces Pricing of Initial Public Offering

June 17, 2021 11:15 PM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), today announced the pricing of its initial public offering of 7,000,000 American depositary shares (ADSs), each representing seven ordinary shares, at a public offering price of $18.00 per ADS.

The total gross proceeds to Ambrx from the offering are expected to be $126.0 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Ambrx has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 ADSs at the initial public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Ambrx.

The shares are expected to begin trading on the New York Stock Exchange on June 18, 2021 under the ticker symbol “AMAM”. The offering is expected to close on June 22, 2021, subject to the satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, BofA Securities and Cowen are acting as joint book-running managers for the offering.

Zenith

1. Zenith was founded in 2013 after years of drug development within the RVX umbrella.
2. Dr Lakhotia and the ZE team have established valuable relationships with numerous big pharmaceutical companies and the NCI in the cancer space with a number of promising trials in place.
3. However, on the ZCC side of the business no progress has been achieved on creating shareholder value and liquidity.

As with Resverlogix the Achilles heel remains with the CEO suite.

Perhaps Don is the patient and wise old man holding on until there is finally some proof that zen3694 and apabetalone actually work. After all, his compensation commities are now paying him a comfortable joint salary of $600,000 plus/year. Why rush? Lucky for him that the ZE team is moving things forward. The same cannot be said for the RVX team.

Just some reflections.

Toinv